Fig. 5.
Fig. 5. The effect of repeated incubations of chimpanzee A-264 (A) and human platelets (B) with chimpanzee A-264 plasma on binding of DDAbs in the presence of 10 μmol/L drug as measured by relative fluorescence of FITC-labeled secondary antibody using flow cytometry. (A) One hundred microliters of 2 × 108 platelets/mL was repeatedly incubated with 60 μL of chimpanzee A-264 plasma. (▪) A2-L, (•) A1-L using chimpanzee A-264 plasma; (▴) A2-L, (▿) A1-L using control chimpanzee plasma. (B) Fifty microliters of 1 × 108 platelets/mL was repeatedly incubated with 100 μL of chimpanzee A-264 plasma. (▪) A2-L, (•) A1-L using chimpanzee A-264 plasma; (▴) A2-L using control chimpanzee plasma.

The effect of repeated incubations of chimpanzee A-264 (A) and human platelets (B) with chimpanzee A-264 plasma on binding of DDAbs in the presence of 10 μmol/L drug as measured by relative fluorescence of FITC-labeled secondary antibody using flow cytometry. (A) One hundred microliters of 2 × 108 platelets/mL was repeatedly incubated with 60 μL of chimpanzee A-264 plasma. (▪) A2-L, (•) A1-L using chimpanzee A-264 plasma; (▴) A2-L, (▿) A1-L using control chimpanzee plasma. (B) Fifty microliters of 1 × 108 platelets/mL was repeatedly incubated with 100 μL of chimpanzee A-264 plasma. (▪) A2-L, (•) A1-L using chimpanzee A-264 plasma; (▴) A2-L using control chimpanzee plasma.

Close Modal

or Create an Account

Close Modal
Close Modal